ストックスクリーナーアプリを入手
0.5351
2.90%
0.0151
プレマーケット:
.51
-0.0251
-4.69%
Ensysce Biosciences Inc (ENSC) 最新ニュース
Price Action: Will Ensysce Biosciences Inc benefit from geopolitical trendsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Bull Run: Is Ensysce Biosciences Inc subject to activist investor interest2026 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences (NASDAQ: ENSC) registers 20.3M resale shares - Stock Titan
Ensysce Biosciences Secures $2 Million Second Tranche Financing to Advance Abuse-Resistant Pain Therapies - Minichart
Ensysce Biosciences Secures $2 Million Private Financing - TipRanks
Ensysce Biosciences (NASDAQ: ENSC) closes $2M preferred and warrant deal - Stock Titan
Ensysce Raises $2 Million in Private Placement of Series B Preferred and Warrants - TradingView — Track All Markets
Ensysce Biosciences closes $2M convertible preferred financing By Investing.com - Investing.com South Africa
Ensysce Biosciences Secures Second Financing to Advance Pain Programs - National Today
Ensysce Biosciences closes $2M convertible preferred financing - Investing.com
Pain drug developer pulls another $2M for overdose-resistant treatments - Stock Titan
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - The Globe and Mail
Aug Swings: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
Stop Loss: Whats the RSI of PETWW stock2026 Sector Review & Real-Time Volume Triggers - baoquankhu1.vn
Ensysce Biosciences, Inc. Announces Director Resignation in April 2026 Form 8-K Filing - Minichart
Ensysce Biosciences director Curtis Rosebraugh resigns from board By Investing.com - Investing.com India
Ensysce Biosciences director Curtis Rosebraugh resigns from board - Investing.com
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation - TipRanks
Board member Curtis Rosebraugh exits Ensysce Biosciences (NASDAQ: ENSC) - Stock Titan
ENSC SEC FilingsEnsysce Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences, Inc. — Business Overview, Risk Factors, Regulatory Approvals, and Intellectual Property Challenges 64 - Minichart
8-K: Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - bitget.com
Smart Money: Will Ensysce Biosciences Inc benefit from geopolitical trendsWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ensysce Biosciences (NASDAQ: ENSC) outlines abuse-resistant opioid pipeline - Stock Titan
ENSC: Net loss widened to $10.2 million in 2025; ongoing operations depend on new capital raises - TradingView — Track All Markets
Ensysce Biosciences Reports Q4 and Full Year 2025 Results - National Today
Ensysce (NASDAQ: ENSC) advances PF614 programs as 2025 net loss hits $10.2M - Stock Titan
Ensysce Biosciences Q4 net loss narrows to $2.8 mln - TradingView
Ensysce pushes abuse-deterrent opioid into late-stage testing - Stock Titan
Ensysce Biosciences (NASDAQ: ENSC) director quits after opposing retention deals - stocktitan.net
Revenue Check: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State - Minichart
Ensysce Biosciences files correction to Series B preferred stock designation By Investing.com - Investing.com South Africa
Ensysce Biosciences Corrects Series B Preferred Stock Designation - TipRanks
Ensysce Biosciences files correction to Series B preferred stock designation - Investing.com
Ensysce Biosciences (ENSC) files correction to Series B preferred stock - Stock Titan
If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - Stock Titan
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Analysis: Is Ensysce Biosciences Inc being accumulated by smart money2026 Setups & Daily Profit Focused Screening - baoquankhu1.vn
Ensysce Biosciences Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
ENSC Earnings History & Surprises | EPS & Revenue Results | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Market Fear: Will Ensysce Biosciences Inc benefit from geopolitical trendsJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Pl - PharmiWeb.com
CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan
Ensysce publishes phase 1 data on overdose-limiting opioid tech By Investing.com - Investing.com Australia
ENSC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Ensysce publishes phase 1 data on overdose-limiting opioid tech - Investing.com India
New opioid design limits drug release when too many pills are swallowed - Stock Titan
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):